Company intelligence / Profile preview

Taewoong Medical

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Taewoong Medical’s products are CE-marked and FDA-cleared for use in multiple countries. Their Niti-S™ line of metallic stents has demonstrated safety and efficacy for palliation of malignant biliary strictures and other GI/urologic indications. The company also offers radiofrequency ablation devices for minimally invasive treatment of soft tissue lesions[9][1][2].

Therapeutic areas: OncologyGastroenterologyMen's Health
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

Niti-S

Commercial

Indications: Gastrointestinal obstruction, Biliary obstruction

2 more assets in the full pipeline.

Request access →

Partnerships

Distributed by Pyramed in Australia as part of Device Technologies’ portfoliodistributed by Prion Medical in Belgiumdistributed by Healthcare21 in Europe

Beyond the preview

Go deeper on Taewoong Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taewoong Medical.

Explore the full profile